JP2024513692A5 - - Google Patents
Info
- Publication number
- JP2024513692A5 JP2024513692A5 JP2023555769A JP2023555769A JP2024513692A5 JP 2024513692 A5 JP2024513692 A5 JP 2024513692A5 JP 2023555769 A JP2023555769 A JP 2023555769A JP 2023555769 A JP2023555769 A JP 2023555769A JP 2024513692 A5 JP2024513692 A5 JP 2024513692A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cancer
- seq
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021080142 | 2021-03-11 | ||
| CNPCT/CN2021/080142 | 2021-03-11 | ||
| CNPCT/CN2022/076516 | 2022-02-16 | ||
| CN2022076516 | 2022-02-16 | ||
| PCT/CN2022/080297 WO2022188856A1 (en) | 2021-03-11 | 2022-03-11 | Method of treating diseases using gremlin1 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513692A JP2024513692A (ja) | 2024-03-27 |
| JP2024513692A5 true JP2024513692A5 (enExample) | 2025-03-19 |
Family
ID=83226314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555769A Pending JP2024513692A (ja) | 2021-03-11 | 2022-03-11 | グレムリン１アンタゴニストを使用して疾患を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240190950A1 (enExample) |
| EP (1) | EP4304646A4 (enExample) |
| JP (1) | JP2024513692A (enExample) |
| KR (1) | KR20230156936A (enExample) |
| CN (1) | CN116940380A (enExample) |
| AU (1) | AU2022233762A1 (enExample) |
| BR (1) | BR112023018204A2 (enExample) |
| CA (1) | CA3213121A1 (enExample) |
| MX (1) | MX2023010594A (enExample) |
| TW (1) | TW202300527A (enExample) |
| WO (1) | WO2022188856A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022152290A1 (en) * | 2021-01-18 | 2022-07-21 | Suzhou Transcenta Therapeutics Co., Ltd. | Novel anti-gremlin1 antibodies |
| CN120957750A (zh) * | 2023-04-13 | 2025-11-14 | 苏州创胜医药集团有限公司 | 用于治疗癌症的涉及grem1拮抗剂的组合疗法 |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
| CN119746060B (zh) * | 2025-03-07 | 2025-09-16 | 南昌大学第一附属医院 | 一种树突状细胞疫苗制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2826790B1 (en) * | 2012-03-15 | 2019-02-13 | SNU R&DB Foundation | Anti-gremlin-1 antibody |
| EA201591762A1 (ru) * | 2013-03-14 | 2015-12-30 | Ридженерон Фармасьютикалз, Инк. | Человеческие антитела к grem1 |
| CA3030582A1 (en) * | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| GB201621635D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| MX2020013808A (es) * | 2018-06-18 | 2021-05-27 | UCB Biopharma SRL | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. |
| WO2022152290A1 (en) * | 2021-01-18 | 2022-07-21 | Suzhou Transcenta Therapeutics Co., Ltd. | Novel anti-gremlin1 antibodies |
-
2022
- 2022-03-11 EP EP22766378.8A patent/EP4304646A4/en active Pending
- 2022-03-11 MX MX2023010594A patent/MX2023010594A/es unknown
- 2022-03-11 CA CA3213121A patent/CA3213121A1/en active Pending
- 2022-03-11 TW TW111109016A patent/TW202300527A/zh unknown
- 2022-03-11 AU AU2022233762A patent/AU2022233762A1/en active Pending
- 2022-03-11 WO PCT/CN2022/080297 patent/WO2022188856A1/en not_active Ceased
- 2022-03-11 JP JP2023555769A patent/JP2024513692A/ja active Pending
- 2022-03-11 US US18/549,928 patent/US20240190950A1/en active Pending
- 2022-03-11 BR BR112023018204A patent/BR112023018204A2/pt unknown
- 2022-03-11 CN CN202280020454.8A patent/CN116940380A/zh active Pending
- 2022-03-11 KR KR1020237034659A patent/KR20230156936A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024513692A5 (enExample) | ||
| AU2018246873B2 (en) | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene | |
| US7498142B2 (en) | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies | |
| EP3237006B1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| JP2024504124A5 (enExample) | ||
| Zhu et al. | Multifunctional receptor-targeting antibodies for cancer therapy | |
| JP2010518820A5 (enExample) | ||
| EP3600411B1 (en) | Antibodies for the treatment of erbb-2/erbb-3 positive tumors | |
| JP2022526841A5 (enExample) | ||
| CN116940380A (zh) | 使用grem1拮抗剂治疗疾病的方法 | |
| US20260103526A1 (en) | Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof | |
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 | |
| US9464136B2 (en) | Antibody-based constructs directed against tyrosine kinase receptors | |
| JP2024517600A5 (enExample) | ||
| JP2024542879A5 (enExample) | ||
| JPWO2016163433A1 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| WO2024213066A1 (en) | Combination therapies involving grem1 antagonists for treatment of cancer | |
| RU2853818C1 (ru) | Способ лечения заболеваний с применением антагонистов GREMLIN1 | |
| RU2853818C9 (ru) | Способ лечения заболеваний с применением антагонистов GREMLIN1 | |
| JP2026514105A (ja) | 癌の治療のためのｇｒｅｍ１拮抗薬が関与する併用療法 | |
| JP2025512888A5 (enExample) | ||
| HK40094175A (zh) | 使用grem1拮抗剂治疗疾病的方法 | |
| TW202540198A (zh) | 雙特異性抗體樣蛋白以及彼之製造及使用方法 | |
| RU2025134255A (ru) | Конъюгат антитела к рецептору эпидермального фактора роста (egfr) и лекарственного средства и его применение | |
| RU2022107092A (ru) | Новые анти-cldn18.2 антитела |